Non-toxigenic C. difficile Spore Vaccine for Antibiotic Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Clostridium difficile infections are hindered by antibiotic resistance and the protective effects of spore formation, necessitating an effective prevention and treatment method.
Innovation Solution
Development of genetically modified non-toxigenic Clostridium difficile strains and vaccines using spores formed by these strains, which include immunogenic proteins with specific domain substitutions, administered to induce anti-TcdA and anti-TcdB IgG antibodies for immune protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic treatment is used for Clostridium difficulte infections, then the infection can be treated, but antibiotic resistance and physiological factors (spore formation, pseudomembrane protection) make treatment difficult and less effective
Solution Approach 1:
The patent converts the harmful spore-forming capability of C. difficile into a beneficial feature by using spores as the vaccine delivery vehicle. The spores that normally cause infection are instead utilized as stable, resistant carriers of immunogenic proteins to elicit protective immunity, thereby transforming the pathogen's survival mechanism into a therapeutic advantage
Solution Approach 2:
The patent introduces non-toxigenic C. difficile strains expressing immunogenic proteins as intermediaries between the harmful pathogen and the immune system. These modified strains serve as vaccine vectors that deliver protective antigens without causing disease, mediating immunity against the actual pathogen through controlled exposure to safe, modified forms
2Reliability
If toxigenic C. difficulte strains are used for vaccination, then immunity can be induced, but the toxins (TcdA, TcdB) cause severe disease and death
Solution Approach 1:
The patent extracts and separates the immunogenic domains (receptor binding domains of TcdA and TcdB) from the toxic components (glucosyltransferase and cysteine proteinase domains). By taking out only the necessary protective elements and removing the harmful toxin-producing capabilities, the vaccine achieves immunity induction without causing disease
Solution Approach 2:
The patent applies local quality modification by creating non-toxigenic strains that locally express immunogenic proteins in specific domains (receptor binding domains) while eliminating toxin production capabilities in other domains. This selective expression allows the vaccine to provide protection without the harmful effects of full-length toxins
3Object-affected harmful factors
If genetically modified non-toxigenic strains are created, then safety is improved, but the complexity of strain construction and immunogenic protein expression increases
Solution Approach 1:
The patent segments the C. difficulte genome and protein expression system into distinct functional components: immunogenic protein expression cassettes, toxin production suppression elements, and spore formation maintenance. This segmentation allows independent optimization of each component and simplifies the overall strain construction process by treating each function separately
Data Source
AI summary
Described are non-toxigenic Clostridium difficile strains and spores. Also described are vaccines comprising the Clostridium difficile spores. Further described are methods of preventing or treating a Clostridium difficile infection in a subject in need thereof.